Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

PD-L1/PD-1 blockade immunotherapy has significantly improved treatment outcome for several cancer types compared to conventional cytotoxic therapies. However, the specific molecular and cellular mechanisms behind its efficacy are currently unclear. There is increasing evidence in murine models and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuazo, Miren, Arasanz, Hugo, Bocanegra, Ana, Fernandez, Gonzalo, Chocarro, Luisa, Vera, Ruth, Kochan, Grazyna, Escors, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734243/
https://www.ncbi.nlm.nih.gov/pubmed/33329566
http://dx.doi.org/10.3389/fimmu.2020.586907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734243/
https://www.ncbi.nlm.nih.gov/pubmed/33329566
http://dx.doi.org/10.3389/fimmu.2020.586907

Ejemplares similares